 Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.  Americas+1 212 318 2000  EMEA+44 20 7330 7500  Asia Pacific+65 6212 1000   Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.  Americas+1 212 318 2000  EMEA+44 20 7330 7500  Asia Pacific+65 6212 1000  By Stephanie Bodoni and Samuel Stolton Pfizer Inc.âs $43 billion takeover of Seagen Inc. faces a European Union review after the companies formally notified the blocâs merger watchdog. The European Commission set Oct. 19 as a deadline to complete its initial probe, according to a filing on its website on Friday.  Seagen is a leader in developing a type of medicine called antibody-drug conjugates which help to deliver cancer-killing drugs so potent they might otherwise be too toxic to use. Seagenâs portfolio will double Pfizerâs pipeline of early-stage experimental cancer therapies, the company said when it announced the tie-up in March.  Pfizer, which has been ...  AI-powered legal analytics, workflow tools and premium legal & business news.   Log in to keep reading or access research tools. 